FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2773826105> ?p ?o ?g. }

• W2773826105 endingPage "80" @default.
• W2773826105 startingPage "73" @default.
• W2773826105 abstract "Serious recurrent bacterial infections are a major cause of morbidity and mortality in children infected with the human immunodeficiency virus (HIV). Because intravenous immune globulin has been shown to prevent bacterial infection in patients with primary immunodeficiency and in uncontrolled studies of HIV-infected children, we undertook a multicenter study of its safety and efficacy in children with symptomatic HIV infection.In a double-blind trial, 372 HIV-infected children (mean age, 40 months) with clinical or immunologic evidence of HIV disease were randomly assigned to receive either intravenous immune globulin (400 mg per kilogram of body weight) or placebo (0.1 percent albumin) every 28 days. The children were stratified into two groups according to CD4+ lymphocyte count at entry into the study and the clinical classification of the Centers for Disease Control. The median length of follow-up was 17 months.For children in either group with CD4+ counts greater than or equal to 0.2 x 10(9) per liter (greater than or equal to 200 per cubic millimeter) at entry, treatment with intravenous immune globulin significantly increased the time free from serious infection; estimated infection-free rates after 24 months were 67 percent for children receiving immune globulin as compared with 48 percent for those receiving placebo (P = 0.01). In addition, immune globulin was associated with an overall reduction in the number of both serious and minor bacterial infections (relative risk, 0.68; P = 0.01) and in the number of hospitalizations for acute care (relative risk, 0.65; P = 0.03). No such benefits were seen for children with CD4+ counts below 0.2 x 10(9) per liter at entry. For group 1 overall, there was a trend toward a difference in serious bacterial infection between immune globulin and placebo (24-month infection-free survival, 31 percent for intravenous immune globulin vs. 25 percent for placebo; P = 0.10). For group 2, the estimates of survival without serious infection were 73 percent with intravenous immune globulin as compared with 53 percent with placebo (P = 0.04). There was no effect of treatment on mortality for any group or CD4+ count at entry. Adverse reactions, noted for less than 1 percent of infusions, were minor.In symptomatic HIV-infected children the prophylactic use of intravenous immune globulin, is safe, and it significantly increases the time free from serious bacterial infections for those entering treatment with CD4+ lymphocyte counts greater than or equal to 0.2 x 10(9) per liter." @default.
• W2773826105 created "2017-12-22" @default.
• W2773826105 creator A5002278563 @default.
• W2773826105 creator A5004246889 @default.
• W2773826105 creator A5004677289 @default.
• W2773826105 creator A5006350106 @default.
• W2773826105 creator A5006833807 @default.
• W2773826105 creator A5007707615 @default.
• W2773826105 creator A5008789818 @default.
• W2773826105 creator A5008960911 @default.
• W2773826105 creator A5013753700 @default.
• W2773826105 creator A5013829111 @default.
• W2773826105 creator A5014941193 @default.
• W2773826105 creator A5016365640 @default.
• W2773826105 creator A5016786245 @default.
• W2773826105 creator A5017454718 @default.
• W2773826105 creator A5017901622 @default.
• W2773826105 creator A5023876677 @default.
• W2773826105 creator A5028032774 @default.
• W2773826105 creator A5028793640 @default.
• W2773826105 creator A5029038051 @default.
• W2773826105 creator A5032224704 @default.
• W2773826105 creator A5032633861 @default.
• W2773826105 creator A5035212092 @default.
• W2773826105 creator A5035313938 @default.
• W2773826105 creator A5037322068 @default.
• W2773826105 creator A5037597322 @default.
• W2773826105 creator A5038835446 @default.
• W2773826105 creator A5040492797 @default.
• W2773826105 creator A5048297938 @default.
• W2773826105 creator A5049366417 @default.
• W2773826105 creator A5049562614 @default.
• W2773826105 creator A5052461812 @default.
• W2773826105 creator A5053855029 @default.
• W2773826105 creator A5057128338 @default.
• W2773826105 creator A5057665931 @default.
• W2773826105 creator A5058432689 @default.
• W2773826105 creator A5058873951 @default.
• W2773826105 creator A5059718104 @default.
• W2773826105 creator A5061592226 @default.
• W2773826105 creator A5065593774 @default.
• W2773826105 creator A5069410276 @default.
• W2773826105 creator A5070528910 @default.
• W2773826105 creator A5071386719 @default.
• W2773826105 creator A5075465290 @default.
• W2773826105 creator A5083462585 @default.
• W2773826105 creator A5083778112 @default.
• W2773826105 creator A5084302638 @default.
• W2773826105 creator A5086109339 @default.
• W2773826105 creator A5086432190 @default.
• W2773826105 creator A5090959821 @default.
• W2773826105 creator A5091541675 @default.
• W2773826105 date "1991-07-11" @default.
• W2773826105 modified "2023-10-01" @default.
• W2773826105 title "Intravenous Immune Globulin for the Prevention of Bacterial Infections in Children with Symptomatic Human Immunodeficiency Virus Infection" @default.
• W2773826105 cites W121740414 @default.
• W2773826105 cites W1500702221 @default.
• W2773826105 cites W1972713890 @default.
• W2773826105 cites W1972860656 @default.
• W2773826105 cites W1980494192 @default.
• W2773826105 cites W1991883424 @default.
• W2773826105 cites W1996414664 @default.
• W2773826105 cites W2000249467 @default.
• W2773826105 cites W2005526186 @default.
• W2773826105 cites W2006869076 @default.
• W2773826105 cites W2007610268 @default.
• W2773826105 cites W2042391678 @default.
• W2773826105 cites W2045693849 @default.
• W2773826105 cites W2050200780 @default.
• W2773826105 cites W2078595434 @default.
• W2773826105 cites W2086244240 @default.
• W2773826105 cites W2094197132 @default.
• W2773826105 cites W2124467421 @default.
• W2773826105 cites W2312733322 @default.
• W2773826105 cites W2328998233 @default.
• W2773826105 cites W2336197601 @default.
• W2773826105 cites W2467022164 @default.
• W2773826105 doi "https://doi.org/10.1056/nejm199107113250201" @default.
• W2773826105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1675763" @default.
• W2773826105 hasPublicationYear "1991" @default.
• W2773826105 type Work @default.
• W2773826105 sameAs 2773826105 @default.
• W2773826105 citedByCount "231" @default.
• W2773826105 countsByYear W27738261052012 @default.
• W2773826105 countsByYear W27738261052013 @default.
• W2773826105 countsByYear W27738261052014 @default.
• W2773826105 countsByYear W27738261052015 @default.
• W2773826105 countsByYear W27738261052016 @default.
• W2773826105 countsByYear W27738261052017 @default.
• W2773826105 countsByYear W27738261052018 @default.
• W2773826105 countsByYear W27738261052023 @default.
• W2773826105 crossrefType "journal-article" @default.
• W2773826105 hasAuthorship W2773826105A5002278563 @default.
• W2773826105 hasAuthorship W2773826105A5004246889 @default.
• W2773826105 hasAuthorship W2773826105A5004677289 @default.
• W2773826105 hasAuthorship W2773826105A5006350106 @default.
• W2773826105 hasAuthorship W2773826105A5006833807 @default.
• W2773826105 hasAuthorship W2773826105A5007707615 @default.

• next